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Summary 
Activation studies performed with transfected T cell hybridomas and tumors revealed that chimeric 
molecules containing the CD3e or ~" chain intracytoplasmic portions can induce the complete 
effector functions normally seen only when the complete T cell receptor (TCR)/CD3 complexes 
of T lymphocytes are triggered. Therefore, the ~" chain, with its three antigen recognition activation 
motives, is thought to connect the antigen-binding Ti chains with the intracellular signaling 
machinery of the T cell. Here we demonstrate that the cytoplasmic portion of the TCP,-~" chain 
is not sufficient to activate resting T  lymphocytes when cells from transgenic mice expressing 
a chimeric ~" receptor are used.  However, after  (in vivo and in vitro) activation through their 
endogenous TCP,/CD3 complexes, the preactivated T lymphocytes could be triggered through 
the ~'chimera to the same extent as when they were activated through their endogenous TCP,/CD3 
complexes. They were able to proliferate and elicit cytotoxic functions when triggered through 
their ~" chimeras.  These results suggest that the triggering requirements for effector functions 
seem  to be different  in resting than in activated  T  cells. 
T 
CR is a complex multisubunit structure composed of 
at least six different protein chains  (TCR-ot, TCR-13, 
CD33', CD35, CD3e, and ~" or its alternative splice-product 
7)- The TCR-a and -/~ chains are clonotypically distributed 
and recognize peptide-Ag presented on MHC molecules by 
APC or target cells (1), while the CD3 components y, 8, 
e  (2),  and ~'(~) (3)  are invariant  proteins present in every 
TCR/CD3 complex. They are noncovalently associated with 
each other and TCR-cz//3 heterodimers and are necessary for 
correct assembly, transport, and surface expression of the whole 
TCR/CD3 complex (4). Since the TCR-ot and -/3 proteins 
have no or little intracytoplasmic domains, the invariant CD3 
and ~'(~) proteins are thought to couple the Ag-recognizing 
TCP..-ot/t5 proteins to an intracellular signaling machinery 
(5).  Chimeric receptors,  in which cytoplasmic domains of 
the ~', ~/, CD3e, and FceP-.Iy chains were fused to other ex- 
tracellular  domains  (6-9),  further  supported  the  signal- 
transducing functions of these proteins. The chimeric receptors 
could be expressed in T cell hybridomas and tumors indepen- 
dently of TCR, and, upon cross-linking early and late signal- 
transducing events comparable to those observed after trig- 
gering of the whole multicomponent TCP,/CD3 complexes, 
could be observed. 
A conserved sequence motif in the cytoplasmic domains 
of ~" and T/is required for signal transduction (6, 9-13). This 
Ag recognition activation motif (ARAM) 1 is built up of 
1Abbreviations used in  this paper: ARAM,  Ag  recognition  activation 
motives;  h,  human. 
paired tyrosines and leucines (Y-XX-L-XT_s-Y-XXL)  (10). 
Within the group of ARAM-carrying proteins (CD33', 8, 
e; 13 subunit of the high affinity IgE receptor,  ~', ~/, FceRI3'), 
the ~" and ~/chains are unique, because they contain multiple 
ARAMs (three or two, respectively). Due to this multimeri- 
zation of ARAMs, as well as their functional superiority in 
chimeric receptor studies, it was thought that signals through 
~'/~ chains alone were sufficient to trigger T cells, while other 
ARAM-containing CD3 chains could then only enhance this 
central signal. However, since these conclusions were drawn 
from studies which were carried out with T cell hybridomas 
or tumors representing potentially fully differentiated cells, 
we wanted to investigate whether the ~" chain had similar 
properties in normal resting peripheral T lymphocytes. We, 
therefore,  created transgenic mice that expressed a chimeric 
single chain TCR consisting of the intracellular and trans- 
membrane portion of the ~" chain and an extracellular  do- 
main formed by a CD8ot hinge region and a single chain 
Ab (Fv) portion derived from an mAb specific for human 
(h) CD3e. Confirming the earlier studies using lymphoma 
systems, we previously demonstrated that this chimeric mol- 
ecule can recognize Ag and subsequently transduce signals 
into transfected T cell lymphomas and hybridomas that lead 
to IL-2 and IL-3 production, indistinguishable from IL produc- 
tion induced by normal TCR--MHC interaction (14). 
We demonstrate in this report that, in contrast to the hy- 
bridoma/lymphoma systems used in previous studies,  the 
function of this protein is absolutely dependent upon the 
activation status  of the T  cell.  The chimeric ~" chain can- 
not substitute for the complete TCR/CD3 complex in nor- 
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the ~" chimera.  In contrast,  a triggering through the ~" chi- 
mera induces proliferation and effector functions only in pre- 
viously activated T  cells. Our results suggest that individual 
ARAM-containing  chains in the TCR/CD3  complex may 
have qualitatively different functions, which can control the 
T  cell triggerability  in  different physiological situations. 
Materials  and  Methods 
DNA Constructs  and Microinjection.  The plasmid pHbAPr-l-neo- 
FvCD3~', used for the protoplast fusions, was previously described 
(14). To express the same FvCD3~" protein in transgenic mice, we 
cloned  the  1.6-kb  XhoI-HindIII(blunt)  DNA  fragment  from 
pHjSAPr-l-neo-FvCD3~" into the XhoI-NdeI(blunt)-opened pBlue- 
script KS, which already contained a 1.1-kb HindlII-SalI polyA frag- 
ment  from the plasmid  pBG312  (16).  Subsequently,  we PCg- 
amplified a 600-bp fragment containing the TCR-c~ promoter re- 
gion from pV~CI~EnhH (K. Karjalainen, unpublished  results) with 
the oligonucleotides 7698 and 7573. This PCR fragment was cut 
XhoI and SalI in the oligonucleotide regions and cloned into the 
XhoI-opened  intermediate  construction  already  containing  the 
FvCD3~" portion and the polyA region. In front of this TCRo~ 
promoter region, we then cloned a 5.5-kb NotI-XbaI fragment 
from vector GSE1515 (16) containing the human CD2 YUT re- 
gion. After digestion with NotI and ApaI,  the transgene DNA 
was separated from the vector sequences by electrophoresis, extracted 
from agarose gel slices, and resuspended in Tris-EDTA buffer (10 
mM Tris, pH 7.4; 0.1 mM EDTA). Fertilized oozytes were ob- 
tained from BDF1  ￿  BDF1 mice,  and DNA injection was per- 
formed as previously described (17). 
To transfect the mouse EL4 thymoma with the cDNA encoding 
for the human CD3e chain, we PCR-amplified, with oligonucleo- 
tides 8003 and 8013, a 1-kb fragment from plasmid pDJ4 (18), con- 
taining the human CD3e-cDNA and digested in the oligonucleo- 
tide regions with HindI and SalI, and cloned it into the HindI- 
SalI-opened vector pHflAPR-l-neo. 
The sequences of the used oligonucleotide primers are: 5'ACT- 
TAGTCGACTTTCTGAGCCACTCK;A3' (7698); 5~TCTAGTCG- 
ACATGCAGTCGGGCACTCAC3'(7573); 5'GTAACAGTCGAC- 
TGAAACAAAGATGCAGTCGGGC3'(8003);  5'TAGCTAAGC- 
TTCAGC~CCq~TGTCAACATI'TACC3' (8013) (see reference 18). 
Cell Lines, mA bs, and Reagents.  14.3d, a mouse Th hybridoma 
(derived from the T  cell clone Vz-ls) (19), Jurkat,  a human leu- 
kemic T cell line, and EL4, a mouse lymphoma (ATCC, TIB39), 
were maintained in IMDM,  supplemented with 10% FCS, peni- 
cillin,  streptomycin, and 2-mercaptoethanol. Chimera-transfected 
14.3d clones were passaged in the above medium with the addition 
of Geneticin (Gibco Laboratories,  Grand Island,  NY) at 2 mg/ml 
and hCD3c-transfected  EL4-clones at 0. 7 mg/ml Geneticin for 14 d. 
The protoplastfusion was performed as previously described (14), 
and clones were obtained by limiting dilution and screened for pro- 
tein expression by flow cytometry (see below). 
The mAbs  used in  this  study were anti-FvCD3  A1.3,  a rat 
anti-mouse mAb (14), 2Cll, a hamster anti-mouse CD36 mAb 
(20), a goat anti-rat Ig serum from Southern Biotechnology As- 
sociates (Birmingham, AL). The mAbs specific  for CD4 (No. 09005) 
and L-selectin (Mel-14, No. 01264) were purchased from PharMingen 
(San Diego, CA). 
Flow Cytometry and Cell Sorting.  Expression of cell surface pro- 
teins was assayed by indirect immunofluorescence. Cell suspensions 
of 1  x  105 viable cells were stained with 20 #g/ml mAb that was 
either direct labeled or biotinylated. After washing and the op- 
tional addition of the second step reagent, streptavidin-phycoerythrin 
(Becton Dickinson & Co., Mountain View, CA) cells were fixed 
in  1% paraformaldehyde before cytofluometric analysis, using a 
FACScan  |  (Becton Dickinson & Co.). 
Optionally, the stained cells were sorted under sterile conditions 
into pure FCS on a cell sorter (FACS  |  Vantage; Becton Dickinson 
& Co.). 
Flow Cytometric Determination of[Ca2+~.  0.5  x  10  s T lympho- 
cytes were loaded with 5 gM Indo-l-AM (Sigma Chemical Co., 
St. Louis, MO) for 45 rain at 37~  in 5% FCS Hepes-buffered 
RPMI  medium,  washed once, and analyzed in  the presence  of 
different mAbs or sera on a cytofluorimeter (Elite Flow; Coulter 
Corp., Hialeah, FL) to detect Ca  2+ fluxes. Only live (based on for- 
ward and side scatter criteria) and loaded  cells (based on violet, 
405 nm Ca2§  Indo-1, and blue, 525 nm free Indo-1) were 
included in the analysis. 
Stimulation of T Lymphocytes.  In each assay, 5  x  104 14.3d T 
hybridoma cells, or its transfectants,  were stimulated by different 
amounts of human T  cells, which were fixed before the experi- 
ment by a 30-s treatment with 0.05% glutaraldehyde.  After cocul- 
turing in 200 #1 medium for 20 h, 50 #1 supernatant was collected 
and tested for its interleukin content, using the IL-2-dependent 
cell line cytotoxic T lymphocyte line and the Ib3-dependent cell 
line DA-1, as previously described (14). 
When T lymphocytes from spleen or lymphnodes were used, 
we depleted the cell suspensions from B lymphocytes by incubating 
them  with  sheep  anti-rat  IgG (Dynabeads,  catalogue number 
110.08; DYNAL, Inc., Great Neck, NY) that were coupled before 
the experiment to the mAb 14.8 (21), recognizing the B cell Ag 
8220. The purity ofT lymphocytes reached by this procedure was 
>95%. 
These T cells were usually incubated on Ab-coated 96-well plates 
for 20 h at 2  x  104 cells/well before 1/zCi of [3H]thymidine was 
added for another 12-h period. Incorporation of radioactivity was 
measured by harvesting the cells and measuring their radioactivity 
content on a Betaplate  system (1205; Wallacoy, Turku, Finland). 
When T lymphocytes were prestimulated on 5/~g/ml mAb 2Cll, 
we incubated them for 2-3 d in 75-ml flasks (Costar Corp., Cam- 
bridge, MA), to which this mAb had been coated before. In the 
case where EL4-hCD3e were used to prime the T cells, we irradi- 
ated these stimulator cells with 25,000 rad and added  them in a 
1:1 ratio to the culture. 
Cytotoxicity Assays.  The 4-h SlCr (Amersham  International, 
Little Chalfont, UK)-release assay was performed as previously de- 
scribed  (22). 
Results and Discussion 
The Level of ~" Chimera Cell Surface Expression Does Not 
Correlate with Function in  T  Cell Hybridomas.  To find out 
which level of cell surface expression of the g" chimera was 
necessary to induce effector functions, we transfected the mouse 
helper T cell hybridoma 14.3d with the previously described 
construct pH~APr-l-neo-FvCD3~" (14) that encodes for a chi- 
meric TCR.  This molecule consists of the cytoplasmic and 
transmembrane regions of the ~'chain, a 44-amino acid hinge 
region derived from CDScr and a single chain Ab portion 
(FvCD3), which can recognize the native human CD36 pro- 
tein on the surface of human T cells. Two clones representing 
both extremes of surface expression are described in Table 
1. While 14.3d transfectant 1 shows only very low cell sur- 
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expressor of the same protein as revealed by FACS  |  analysis 
with anti-Fv mAb. When both cells were stimulated with 
Ag (= hCD3)-expressing Jurkat cells,  which were fixed be- 
fore the assay, they nevertheless behaved similarly and could 
produce the same amounts oflL-3 (and IL-2; data not shown), 
while the untransfected 14.3d did not produce any interleukins 
(Table 1). All these hybridomas produced similar amounts of 
IL-2 and IL-3 and in the same range as after ~'chimera stimu- 
lation when they were triggered through  their endogenous 
TCR,  specific  for hemagglutinin  peptide complexed with 
I-E  a MHC  class  II molecules on APCs  (data not  shown). 
These results clearly demonstrate  that  minimal  amounts 
of the  ~" chimera  are sufficient to induce effector functions 
in T  hybridomas in an Ag-dependent way and that  overex- 
pression  of this  signaling  molecule  does  not  enhance  its 
stimulatory effects.  To investigate if this TCR-like function 
of the ~" chain described in hybridomas could also be induced 
in resting T cells, we created transgenic mice that would ex- 
press  this  FvCD3~" chain  on normal  T  lymphocytes. 
Expression of  the ~" Chimera in Transgenic  Mice.  The trans- 
gene constructed for these experiments  codes for the same 
single chain TCR (~" chimera)  as previously described (14), 
but now under the control of the hCD2 3'-flanking sequences 
and TCR-ot promoter  (Fig.  1).  The hCD2 Y-flanking  se- 
quences have previously been described to direct high-level, 
position-independent,  and  T  lineage-specific expression in 
transgenic mice (16). A total of three transgenic founder lines 
were obtained with similar expression patterns when the ex- 
pression of the transgene was monitored with the mAb A1.3 
(14), which recognizes the single chain Fv portion of the chi- 
meric FvCD3~'receptor. This mAb stains  T lymphocytes in 
Table  1.  IL-3 Production of the Hybridoma 14.3d and Two of 
Its  Transfectants during Stimulation with Different Amounts of 
Fixed  Jurkat Cells 
IL-3 [U/ml] 
production  after  stimulation 
with Jurkat  cells 
( x 104 Jurkat) 
Mean fluorescence 
Cells  anti-Fv  3  1  0.3  0.1 
14.3d  3.6  0  0  0  0 
14.3d  I  9.5  11.5  7.5  3.9  1.8 
14.3d  II  160.2  13.8  7.4  3.6  2.1 
Relation between surface  expression level and function of the FvCD3~'- 
chimera in the T hybridoma 14.3d transfectants. Cells were incubated 
first with the biotinylated Fv-specific  mAb A1.3 and then stained with 
streptavidin PE. Staining intensity, as measured on a FACScan  |  is ex- 
pressed as mean fluorescence  intensity. For IL-3 production, 5  x  10  4 
cells were stimulated with different amounts of glutaraldehyde-fixed  Jurkat 
cells, and the IL-3 in the culture supernatants were then determined in 
a bioassay. 
Figure 1.  Restriction map  of the  transgenic construct FvCD3~'. 
FvCD3~'-cDNA (white  box) was placed  under the control of human CD2 
3' UT region (grey  box) and the mouse  TCR-o~  promoter (black  box). The 
poly  A region is depicted  as a striped  box. A, ApaI; H, HindllI; N, Notl; 
Nd, NdeI; X, Xhol; Xb, Xbal. 
whole blood, lymphnode, or splenocyte cell suspensions of 
transgenic mice only. Fig. 2 shows a typical FACS  |  staining 
performed on B220-depleted splenocytes. The lower staining 
shows that transgenic,  as well as nontransgenic cells, display 
similar CD3 expression levels when analyzed with the mAb 
2Cll.  When  the staining was performed with  the anti-Fv 
mAb A1.3, only transgenic cells could be labeled, while cells 
isolated from nontransgenic littermates  remained negative (top). 
Further FACS  |  analysis with anti-CD4 and anti-CD8 mAbs 
showed that  equal levels  of FvCD3~" protein  are expressed 
on both  CD4 §  and  CD8 §  lymphocyte populations  (data 
not shown).  FvCD3~" expression level is also comparable to 
the average  T  cell hybridoma transfectant  described earlier. 
Furthermore,  the ~" chimera seemed not to disturb T  cell 
development, since normal ratios of T lymphocytes could be 
found in the periphery and in the thymus (data not shown). 
Triggering of  the ~" Chimera Does Not Activate Resting T Lym- 
phocytes.  To assess the  function  of our chimeric  FvCD3~" 
chain in resting lymphocytes, we incubated T  lymphocytes 
(B220-depleted splenocytes, >95% pure) with different con- 
centrations of plastic-coupled mAb 2Cll directed against the 
mouse CD3e  molecule of the  TCR/CD3  complex or  the 
mAb A1.3 that recognizes specifically  the Fv portion of the 
chimeric  FvCD3~" protein. 
As expected, the mAb 2Cll induces a proliferative  response 
in an Ab dose-dependent manner (Fig. 3). The [3H]thymi- 
dine uptake shows a plateau  at  ~5  #g/ml  mAb,  at which 
it  starts  to decrease.  In contrast,  when incubated with the 
anti-Fv mAb A1.3, there is no significant  3H incorporation, 
even  at  the  highest  Ab  concentration. 
Furthermore,  it was impossible to stimulate  the resting 
T  lymphocytes through  their FvCD3~" protein,  even when 
the anti-Fv mAb was used in combination with an anti-CD4 
mAb. While the CD4-specific mAb showed a dear costimula- 
tory effect and synergized with low levels of the anti-CD3 
mAb, it did not show any effect when used with the mAb 
A1.3 (Fig. 3). IL-2 or other mAbs which are thought to supply 
an  additional  costimulatory  signal,  such as mAbs directed 
against the coreceptors CD4,  CD8,  CD28,  and CD45, be- 
haved the same way and could not elicit any costimulatory 
effect when  used together  with  the  mAb  A1.3  (data  not 
shown). 
We then monitored intraceUular [Ca  2+ ] levels of the resting 
lymphocytes during  a trigger  of the FvCD3~" molecule on 
their surface and were not able to detect an increase of [Ca  2+] 
(Fig.  4, left). Even the addition of a cross-linking polyclonal 
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Figure  2.  Expression of the transgene leads to detectable 
FvCD3~"  protein cell surface expression. Splenocytes from a 
transgenic mouse were B ceil-depleted,  stained, and analyzed 
by two-color flow cytometry.  Single-color histograms  were 
obtained by gating on the CD3 + population  in two-color 
stainings, using 2C11-FITC and A1.3 biotin plus streptavidin 
PE. The top panel shows the PvCD3~'expression level, while 
the lower panel compares TCR/CD3 expression of transgenic 
vs. nontransgenic  lymphocytes. 
goat anti-rat serum did not induce Ca  2  § flux. The control 
experiment (Fig. 4, right) shows that these resting lympho- 
cytes are very well able to flux Ca  ~+ when triggered through 
their TCR./CD3 complexes by the mAb 2Cll, even without 
additional cross-linking. These data indicate that, unlike the 
full TCR/CD3 complex, the ~" chain alone is not su~cient 
t00(~0 
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Figure  3.  Triggering of FvCD3~" protein does not induce a prolifera- 
tive response in resting T lymphocytes.  B cell-depleted splenocytes were 
cultured for 20 h at 2  x  104 cells/welL [3Hlthymidine  was then added 
and the radioactive  uptake  measured  after another 12 h.  Cultures were 
performed in 96-well plates previously coated with either mAb 2Cll (open 
squares) or mAb A1.3 (open circles) at the indicated concentrations,  or mAb 
2Cll  +  mAb GK1.5 (/;Iled squares) or raAb A1.3  +  mAb GK1.5 (filled 
circles). The anti-CD4 mAb GK1.5 was used at 10/.r  for the costimu- 
lation assays. 
to transduce an activating signal into resting lymphocytes, 
as monitored by [3H]thymidine uptake and [Ca~+]i measure- 
ment. Eventually, other components of the TCR/CD3 com- 
plex have to get involved to make the resting lymphocytes 
progress in the call cycle and start  to proliferate. The fact 
that not even early events, such as increases in [Ca2+]i, could 
be detected indicates that the ~" chain intracytoplasmatic do- 
main alone seems to be incapable of effectively signaling in 
resting T  cells. 
~" Chimera  Induces Proliferation in Preactivated T  Lympho- 
cytes.  Since the ~" intracellular portions of various chimeric 
receptors were able to induce various effector functions (8, 
9,  11,  13,  14) in T cell hybridomas and tumors, but not in 
resting T lymphocytes we wanted to investigate if this dis- 
crepancy was related to the different activation states displayed 
by lymphomas, hybridomas, or lines used in previous studies 
compared to the resting lymphocytes we use in this report. 
We, therefore, prestimulated resting transgenic and non- 
transgenic T lymphocytes via their TCR/CD3 complexes by 
the mAb 2Cll  coupled to plastic.  After 2 d,  the blasting 
cells were removed from the Ab and maintained for another 
24 h in IL-2. Then, we restimulated the T blasts with either 
mAb against TCR/CD3 complexes, or with the mAb A1.3 
recognizing the Fv portion of the ~" chimera. Fig. 5 A shows 
the proliferative response of transgenic lymphocytes to the 
different stimuli. Surprisingly, the Fv-specific Ab is now able 
to induce proliferation of prestimulated transgenic lympho- 
cytes to the same extent and in the same Ab concentration-de- 
pendent fashion as the CD3-specific mAb 2Cll. The prolifer- 
ation  reaches a plateau between 1  and  10/~g/ml  Ab and 
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Figure  4.  Cross-linking of FvCD3~" protein does not induce an increase of [Ca  2+ ]i. Indo-l-loaded T  lymphocytes were incubated with Fv-specific 
mAb A1.3 alone for 3 min and then cross-linked with a goat anti-rat Ig serum (left). In the control experiment (right),  the cells were incubated with 
the mAb 2Cll,  without cross-linking. 
matches the kinetics of proliferation induced by a TCR/CD3 
trigger. In addition, the anti-Fv-induced proliferation (as well 
as the TCR./CD3-induced proliferation) can be elevated by 
the addition of 5 gg/ml CD28-specific mAb to the cultures, 
and, in this respect, is also similarly susceptible to costimula- 
tory signals, such as the TCR/CD3-induced  proliferation￿9 
Fv mAb A1.3 does not induce proliferation in nontransgenic 
lymphocytes, and, as expected, they only proliferate when 
mAb 2Cll  is used (Fig.  5 B). 
These unexpected findings indicate that either the induc- 
tion of proliferation of resting cells needs qualitatively different 
signals from that of preactivated cells,  or that ~" chimera is 
differentially wired to the signal-transducing machinery in 
preactivated cells,  compared to resting cells. 
~" Chimera Mediates Cytotoxicity Only in Preactivated  T Lym- 
phocytes.  To define more precisely the functional potentials 
of the FvCD3~" chimera, we performed killer assays with T 
lymphocytes isolated from B220-depleted transgenic or non- 
transgenic splenocytes. These lymphocytes were either primed 
with the potential target cells EL4-hCD3E, or activated by 
the mAb 2Cll coupled to plastic for 3 d and then tested in 
the cytotoxicity assay on the two different StCr-labeled  target 
cells, EL4 and EL4-hCD3e, respectively. The results in Fig. 
6 show that exposure to the later target cells,  EL4-hCD3e 
(C and D) or EL4 (data not shown), is not sufhdent to prime 
transgenic (as well as nontransgenic) T lymphocytes for specific 
and significant target cell lysis. Since the level of expression 
of hCD3e on the EL4 transfectant, EL4-hCD3e,  was very 
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Figure  5.  Cross-linking of the FvCD3~'chain does in- 
duce a proliferative response in previously activated T lym- 
phocytes. B cell-depleted splenocytes from transgenic (/eft) 
or nontransgenic (right) littermates were preactivated for 
48 h on 2Cll (5 gg/ml), removed from this mAb, and 
kept in Ib2-containing medium for 24 h. Subsequently, 
the T blasts were restimulated with different amounts of 
2Cll (squares) or A1.3 (circles) coupled to plastic plates. 
These cultures were performed either in the presence (filled 
symbols)  or  absence (open symbols)  of  5  gg/ml  anti- 
CD28-specific mAb. 
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Figure  6.  In fully  activated  T lymphocytes,  the FvCD3~" 
chimera is able to induce antigen-specific cytotoxicity. B 
cell-depleted splenocytes  from transgenic  (B and D) or non- 
transgenic (A and C) littermates  were primed either by the 
later targets  EL4-hCD3e (C and D), or activated  by the mAb 
2Cll (A and B). The specific  51Cr release  was measured  after 
a 4-h incubation  period  on either  EL4 (squares)  or EL4-hCD3e 
(circles). 
high (data not shown), we expected that these cells could 
optimally cross-link the FvCD3~" molecules, and, therefore, 
induce priming of the transgenic lymphocytes. However, as 
above, no priming could be detected through the ~" chimera. 
In contrast, when transgenic T  lymphocytes were preacti- 
vated through their TCR/CD3 complexes by the mAb 2Cll, 
they lysed specifically the EL4-hCD3c targets, which were 
recognized by the Fv portion of the FvCD3~" molecule (Fig. 
6 B). Targets (EL4) which didn't express this surface antigen 
(hCD3e) were not lysed. As expected, 2Cll-activated non- 
transgenic T lymphocytes were not able to lyse either target 
(Fig. 6 A). Thus again, triggering of the FvCD3~" chain was 
Table  2.  [3H]thymidine Uptake  in Counts per Minute  of 
CD4 ~, Mel-14 + and CD4 §  Mel-I4-  T  Lymphocytes  after 
Stimulation  with Anti-CD3  or Anti-Fv-Specific  mAb 
Anti-CD3  Anti-Fv 
Cells  (10 #g/ml)  (10/~g/ml) 
Mel-14 §  27,520 (100%)  340 (1.2%) 
Mel-14-  14,158 (100%)  4,012 (27.1%) 
Naturally activated Mel-14- T lymphocytes  can respond to a trigger 
through the FvCD3~"  chimera. Splenocytes  from transgenic mice were 
B cell depleted, stained with mAbs specific for CD4 and Mel-14 (L- 
selectin), and then sorted on a (FACS  |  Vantage, Becton Dickinson & 
Co.) cell sorter. The two sorted populations (CD4+, Mel-14* and 
CD4 +, Mel-14-) were >99% pure and plated at 2 x  104 cells/well  in 
a 96-well plate coated with either the mAb 2Cll (anti-CD3) or A1.3 
(anti-Fv) at 10/zg/ml. Proliferation  was measured  as [3H]thymidine  up- 
take after 20 h. The results shown are counts per minute mean values 
of triplicates with a standard  deviation  of <3%. The average  background 
proliferation of both populations was <250 cpm. 
not sufficient for resting T lymphocytes to be primed (preac- 
tivated) and to reach their full effector functions, as com- 
pared to a prestimulation induced by a trigger of the com- 
plete TCR/CD3 complexes. 
In  Vivo-activated Cells Can Be Directly  Triggered through f 
Chimera.  Mel-14  (L-selectin)  is a marker which has previ- 
ously been reported to distinguish recently activated  (nega- 
tive) T cells from quiescent (positive) T cells (23). To analyze 
whether functionality  of the ~"  chain cytoplasmic portion was 
limited to an in vitro prestimulus through TCR/CD3 by 
mAbs, or if in vivo-activated T  cells would display similar 
features, we sorted T lymphocytes from transgenic mice after 
a staining with mAbs against CD4 vs. Mel-14 and separated 
the Mel-14 + from the Mel-14- population. With this pro- 
cedure,  we  could enrich T  lymphocytes responding  to  a 
stimulus through their FvCD3~" molecule, as shown in Table 
2. While the Mel-14 + T cell population remained unrespon- 
sive to a trigger of their ~" chimera (upper row, 1.2%), the 
Mel-14-  fraction  of the  T  lymphocytes responded  to  a 
significantly higher extent (lower row, 27.1%), as compared 
to a stimulus through their TCR/CD3 complex, which was 
taken as  100%  in each  of these two cell populations. 
These data also indicate that in vivo-activated (Mel-14-) 
T lymphocytes are able to respond to a trigger through their 
~'chimera. This reflects the in vitro findings described in the 
previous sections:  Since the preactivation does not increase 
the level of surface expression  of the  ~" chimera (data  not 
shown), one possible interpretation of the described phenom- 
ena could be that the ~" intracytoplasmic portion is differen- 
tially connected to the signal-transducing machinery in acti- 
vated cells, as compared to resting lymphocytes. Our transgenic 
mice offer us the opportunity to reveal eventual signaling differ- 
ences between resting and activated lymphocytes on the bio- 
chemical level. 
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